Zessly
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Zessly |
|---|---|
| Active Substance | infliksimab |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ograničeni recept |
| Distribution | Supply through pharmacies (community) |
| ATC Code | L04AB02 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
| Educational materials for patients / caregivers |
Kartica s podsjetnikom za bolesnike, verzija listopad 2019 |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o primjeni živih cjepiva u dojenčadi koja je in utero ili tijekom dojenja bila izložena infliksimabu (Flixabi, Inflectra, Remicade, Remsima i Zessly) | 07.03.2022 | Merck Sharp & Dohme d.o.o., Samsung Bioepis NL B.V., Pfizer Croatia d.o.o., Oktal Pharma d.o.o., Sandoz GmbH |
